Niagen Bioscience, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$4.96
+$0.23 (+4.76%) 12:44 PM ET
Prev closePrevC$4.73
OpenOpen$4.83
Day highHigh$4.99
Day lowLow$4.83
VolumeVol406,025
Avg volAvgVol1,250,105
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$375.58M
P/E ratio
24.78
FY Revenue
$129.42M
EPS
0.20
Gross Margin
64.28%
Sector
Healthcare
AI report sections
BULLISH
NAGE
Niagen Bioscience, Inc.
No AI report section text found yet for this symbol.
Volume vs average
Intraday (cumulative)
+67% (Above avg)
Vol/Avg: 1.67×
RSI
52.40(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
-0.00 (Weak)
MACD: -0.00 Signal: 0.00
Short-Term
+0.06 (Strong)
MACD: -0.06 Signal: -0.13
Long-Term
+0.05 (Strong)
MACD: -0.28 Signal: -0.34
Intraday trend score
81.50
LOW71.50HIGH82.50
Latest news
NAGE•2 articles•Positive: 1Neutral: 1Negative: 0
PositiveBenzinga• Eva Mathew
Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion— Stock Jumps After-Hours (UPDATED)
Niagen Bioscience (NASDAQ: NAGE) reported doubled annual profits and 30% revenue growth for 2025, reaching $129.4 million in net sales. CEO Rob Fried announced the company is actively pursuing acquisitions and expanding into new markets including at-home injection kits and cosmetics partnerships. However, 2026 guidance of $145 million (15% growth) appears more modest, and the stock trades 60% below its 52-week high despite strong fundamentals.
Company doubled annual profits, achieved 30% revenue growth beating Wall Street estimates, maintains strong balance sheet with $64.8M cash and no debt, and is actively pursuing strategic growth initiatives including acquisitions, new product launches (at-home injections), and pharma partnerships. However, sentiment is tempered by softer Q4 results, modest 2026 guidance (15% growth), and significant stock underperformance (down 60% from 52-week high despite strong fundamentals).
NeutralGlobeNewswire Inc.• Bbb National Programs
National Advertising Division Finds Certain Reus Cata-Kor NAD+ Claims Supported; Recommends Others Be Modified or Discontinued
The National Advertising Division reviewed claims by Reus Research for its Cata-Kor NAD+ products, finding some claims supported while recommending modifications or discontinuation of others due to insufficient substantiation of health benefits and inadequate influencer disclosures.
Initiated the challenge against Reus Research, but no specific negative outcomes were detailed for the company
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
